Note: Ingredients listed on restricted chemical lists
EC/CAS
7631-86-9
Name of the chemical
Silver adsorbed on silicon dioxide
Concentration
N/A
EC/CAS
14807-96-6
Name of the chemical
Talc
Concentration
N/A
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
EC/CAS
25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
N/A
EC/CAS
238-877-9
Name of the chemical
Talc: Hydrated magnesium silicate
Concentration
N/A
General Information
Revision date
2013-10-28
Product name
Anipryl
Emergency telephone
(24 hours) 1-800-424-9300
Icons in SDS
Company Information
company name
Zoetis Inc
e-mail address of the competent person responsible for the Safety Data Sheet
VMIPSrecords@zoetis.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H373
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Appearance: White tablets
2.1 Classification of the substance or mixture
Acute Oral Toxicity: Category 3 Specific target organ systemic toxicity (repeated exposure): Category 2
EU Classification
EU Indication of danger: Harmful EU Symbol: Xn R22 - Harmful if swallowed. R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.
Signal word
Warning
Hazard statements
H302 - Harmful if swallowed H373 - May cause damage to organs through prolonged or repeated exposure: thymus, spleen, liver.
Precautionary statements
P260 - Do not breathe dust/fume/gas/mist/vapors/spray P264 - Wash hands thoroughly after handling P270 - Do not eat, drink or smoke when using this product P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell P330 - Rinse mouth P314 - Get medical attention/advice if you feel unwell P501 - Dispose of contents/container in accordance with all local and national regulations
2.3 Other hazards
Short Term: May cause eye irritation (based on components) Not expected to cause skin irritation Ingestion may result in mild gastrointestinal irritation with nausea, vomiting, or diarrhea. May cause central nervous system effects Known Clinical Effects: Adverse effects associated with the therapeutic use of selegiline hydrochloride include nausea, dizziness/lightheadedness or fainting, abdominal pain, confusion, hallucinations, dry mouth, vivid dreams, dyskinesias, and headache. Australian Hazard Classification
Hazardous Ingredients
Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
